Veeva Sys Inc Stock Price, News & Analysis

Veeva (NYSE: VEEV) announced that Veeva AI Agents will begin rolling out December 2025 for commercial use, with staged availability across R&D and quality through 2026. Agents are built into the Veeva Vault Platform, provide application-specific prompts and safeguards, and have secure access to Veeva data, documents, and workflows.

Planned availability: Dec 2025 Vault CRM & PromoMats; Apr 2026 Safety & Quality; Aug 2026 Clinical Operations, Regulatory, Medical; Dec 2026 Clinical Data. Veeva AI uses LLMs from Anthropic and Amazon (Bedrock); custom agents can use Veeva-hosted or customer models on Amazon Bedrock or Microsoft Azure AI Foundry. Pricing is usage-based.

Veeva Systems (NYSE:VEEV) released industry research revealing significant challenges in clinical data management. The study found that two-thirds of data managers and clinical research associates (CRAs) believe current inefficiencies threaten future data quality.

Key findings show that data managers spend over 12 hours per week per study on manual data reconciliation, with 97% performing reconciliation outside clinical systems. Major inefficiencies stem from manual data re-entry (68%), disconnected systems (59%), and inefficient workflows (58%).

The research highlights that 71% of data managers expect increased automation in data cleaning over the next two years, while 81% believe connecting clinical systems would improve study execution. However, challenges persist, including protocol complexity (58%), resource constraints (57%), and change resistance (48%).

Veeva Systems (NYSE:VEEV) has announced it will host its 2025 Investor Day virtually on October 16, 2025. The event will run from 1:30 p.m. to 3:30 p.m. PT (4:30 p.m. to 6:30 p.m. ET).

Investors can access the live presentations through Veeva's investor relations website at ir.veeva.com, where an archived version will also be available after the event. Registration for the online event is available through the company's IR website.

Veeva Systems (NYSE:VEEV) announced that Bristol Myers Squibb (BMS) has committed to implementing Veeva Vault CRM, marking a significant expansion of their existing partnership. The collaboration focuses on leveraging AI-powered customer relationship management to enhance healthcare practitioner engagement.

The Vault CRM suite will feature four AI agents - Pre-call Agent, Content Agent, Free Text Agent, and Voice Agent - scheduled for release in December 2025. This technology aims to transform how BMS interacts with healthcare practitioners and streamlines the delivery of information about their medicine portfolio.

Veeva Systems (NYSE:VEEV) announced that Gilead Sciences has committed to implementing Veeva Vault CRM, expanding their existing partnership. The Vault CRM Suite will serve as the foundation for Gilead's commercial execution, featuring advanced AI capabilities including pre-call planning, compliant free text, and voice control functionalities.

This strategic partnership aims to enhance Gilead's commercial operations through Veeva's AI-powered CRM platform, which is designed to improve efficiency and effectiveness in commercial execution. The collaboration represents a significant expansion of the relationship between the two companies, with Gilead's global CIO expressing enthusiasm about exploring Veeva AI's potential.

Veeva Systems (NYSE:VEEV) announced its upcoming participation in Citi's 2025 Global TMT Conference in New York. CFO Brian Van Wagener and EVP Strategy Paul Shawah will deliver a presentation on Thursday, September 4, 2025, at 2:10 p.m. ET.

The presentation will be accessible through a webcast, with both live and archived versions available on Veeva's investor relations website.

Veeva Systems (NYSE:VEEV) announced significant adoption of its Regulatory Information Management (RIM) platform, now used by over 450 companies, including 19 of the top 20 biopharmas. The company has formed strategic partnerships with Accumulus Technologies and DNAnexus to enhance multi-health authority platform integration.

The platform's continuous publishing feature through Veeva Submissions Publishing is being utilized by more than 85 organizations to accelerate submission timelines. Accumulus's network connects over 70 regulatory agencies worldwide, while DNAnexus integration aims to improve inter-agency collaboration for faster product approvals.

Veeva Systems (NYSE:VEEV) has announced a strategic collaboration with Amgen to enhance clinical trial innovation. Amgen will implement the Veeva Clinical Platform to optimize their clinical trial processes and accelerate drug development for serious diseases.

The collaboration includes implementation and change management support from Veeva Business Consulting. Amgen's CIO Scott Skellenger highlighted that this partnership aims to unlock new capabilities for end-to-end trial operations, while Veeva Development Cloud President Jim Reilly emphasized the platform's role in speeding up drug delivery through standardized and connected processes.

Veeva Systems (NYSE:VEEV) reported strong fiscal 2026 second quarter results with total revenues of $789.1M, up 17% year-over-year. Subscription services revenues increased 17% to $659.2M. The company achieved notable financial metrics, including non-GAAP operating income of $352.6M (up 26%) and non-GAAP net income of $333.4M (up 25%).

Key developments include the progress of Veeva AI with planned releases starting December, significant Vault CRM Suite milestones with over 100 customers live, and a strategic partnership with IQVIA. The company updated its FY2026 guidance, projecting total revenues between $3,134M and $3,140M.